Literature DB >> 17330942

Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy.

Rohit G Saldanha1, Mark P Molloy, Khalil Bdeir, Douglas B Cines, Xiaomin Song, Pauliina M Uitto, Paul H Weinreb, Shelia M Violette, Mark S Baker.   

Abstract

Urokinase plasminogen activator (uPA) and its high affinity receptor (uPAR) play crucial proteolytic and non-proteolytic roles in cancer metastasis. In addition to promoting plasmin-mediated degradation of extracellular matrix barriers, cell surface engagement of uPA through uPAR binding results in the activation of a suite of diverse cellular signal transduction pathways. Because uPAR is bound to the plasma membrane through a glycosyl-phosphatidylinositol anchor, these signalling sequelae are thought to occur through the formation of multi-protein cell surface complexes involving uPAR. To further characterize uPAR-driven protein complexes, we co-immunoprecipitated uPAR from the human ovarian cancer cell line, OVCA 429, and employed sensitive proteomic methods to identify the uPAR-associated proteins. Using this strategy, we identified several known, as well as numerous novel, uPAR associating proteins, including the epithelial restricted integrin, alphavbeta6. Reverse immunoprecipitation using anti-beta6 integrin subunit monoclonal antibodies confirmed the co-purification of this protein with uPAR. Inhibition of uPAR and/or beta6 integrin subunit using neutralizing antibodies resulted in the inhibition of uPA-mediated ERK 1/2 phosphorylation and subsequent cell proliferation. These data suggest that the association of beta6 integrin (and possibly other lynchpin cancer regulatory proteins) with uPAR may be crucial in co-transmitting uPA signals that induce cell proliferation. Our findings support the notion that uPAR behaves as a lynchpin in promoting tumorigenesis by forming functionally active multiprotein complexes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17330942     DOI: 10.1021/pr060518n

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  15 in total

Review 1.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

Review 2.  Role of CSF-1 in progression of epithelial ovarian cancer.

Authors:  Setsuko K Chambers
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

Review 3.  Defining the role of integrin alphavbeta6 in cancer.

Authors:  A Bandyopadhyay; S Raghavan
Journal:  Curr Drug Targets       Date:  2009-07       Impact factor: 3.465

4.  ENO1 monoclonal antibody inhibits invasion, proliferation and clone formation of cervical cancer cells.

Authors:  Yuanfeng Gou; Fei Li; Xiaqin Huo; Chunyan Hao; Xiaojuan Yang; Yaping Pei; Na Li; Huiling Liu; Bingdong Zhu
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

5.  Nuclear translocation of urokinase-type plasminogen activator.

Authors:  Victoria Stepanova; Tatiana Lebedeva; Alice Kuo; Serge Yarovoi; Sergei Tkachuk; Sergei Zaitsev; Khalil Bdeir; Inna Dumler; Michael S Marks; Yelena Parfyonova; Vsevolod A Tkachuk; Abd Al-Roof Higazi; Douglas B Cines
Journal:  Blood       Date:  2008-03-12       Impact factor: 22.113

Review 6.  Urokinase and its receptors in chronic kidney disease.

Authors:  Guoqiang Zhang; Allison A Eddy
Journal:  Front Biosci       Date:  2008-05-01

7.  Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.

Authors:  Chi-Hui Tang; Marla L Hill; Alexis N Brumwell; Harold A Chapman; Ying Wei
Journal:  J Cell Sci       Date:  2008-10-21       Impact factor: 5.285

8.  Unique ion signature mass spectrometry, a deterministic method to assign peptide identity.

Authors:  Jamie Sherman; Matthew J McKay; Keith Ashman; Mark P Molloy
Journal:  Mol Cell Proteomics       Date:  2009-06-25       Impact factor: 5.911

9.  Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer.

Authors:  Ryohei Yukimoto; Naohiro Nishida; Tsuyoshi Hata; Shiki Fujino; Takayuki Ogino; Norikatsu Miyoshi; Hidekazu Takahashi; Mamoru Uemura; Taroh Satoh; Yamamoto Hirofumi; Tsunekazu Mizushima; Yuichiro Doki; Hidetoshi Eguchi
Journal:  Cancer Sci       Date:  2021-05-14       Impact factor: 6.716

10.  Three are better than one: plasminogen receptors as cancer theranostic targets.

Authors:  Patrizia Ceruti; Moitza Principe; Michela Capello; Paola Cappello; Francesco Novelli
Journal:  Exp Hematol Oncol       Date:  2013-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.